Use of disulfiram, acamprosate or naltrexone

MESH PheWeb

ALCO_PRESCRIPTION

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Medicine purchases: ATC N07BB01|N07BB03|N07BB04

6321

Check pre-conditions, main-only, mode, ICD version None

2311

Check minimum number of events

Min. number of events 3

2311

Include endpoints None

2311

ALCO_PRESCRIPTION

Extra metadata

Level in the ICD hierarchy 2

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Use of disulfiram, acamprosate or naltrexone based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	2260	755	1505
Unadjusted prevalence (%)	0.73	0.44	1.11
Mean age at first event (years)	42.54	41.19	43.22

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.04	3.22 [1.81, 5.72]	6.6e-5	118
15 years	0.02	2.50 [1.31, 4.78]	5.5e-3	71
5 years	0.00	2.62 [1.30, 5.26]	6.9e-3	16
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: ALCO_PRESCRIPTION – Use of disulfiram, acamprosate or naltrexone
GWS hits: 0

Survival analyses between endpoints

↥

Plot

before Use of disulfiram, acamprosate or naltrexone
after Use of disulfiram, acamprosate or naltrexone

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Use of disulfiram, acamprosate or naltrexone

↥